Results 101 to 110 of about 15,701 (194)

Enavogliflozin Improves Non‐invasive Hepatic Steatosis Indices in Patients With Type 2 Diabetes: A Pooled Analysis of Three Randomised Trials

Diabetes, Obesity and Metabolism, EarlyView.
Min Kyoung Jang, Chang Hee Jung, Han Sol Lee, Areum Lee, Su‐Jin Jeoung, Yong‐Ho Lee, Hae Jin Kim, So Hun Kim, Sung Hoon Yu, Suk Chon, In Kyung Jeong   +10 more
wiley   +1 more source

A Systematic Review and Meta‐Analysis of Semaglutide Effects on Adipose Tissue and Emerging Effects on Brain and Cognition

Obesity Reviews, EarlyView.
ABSTRACT Background In 2023 and 2024, research into semaglutide (SEMA), an antiobesity and antidiabetic medication, indicated potential benefits beyond its approved uses, particularly in preventing Alzheimer's disease (AD). This highlights the link between obesity and AD development.
Amene Saghazadeh, Mahsa Dolatshahi, Soheil Mohammadi, Sara Hosseinzadeh Kassani, Mahshid Naghashzadeh, Joseph E. Ippolito, Claude B. Sirlin, Bettina Mittendorfer, Matthew R. Brier, Suzanne E. Schindler, John C. Morris, Danny Mou, Hani Charles Soudah, Tammie L. S. Benzinger, Cyrus A. Raji   +14 more
wiley   +1 more source

Sodium–glucose cotransporter 2 inhibitors for hypertension in cardiovascular–kidney–metabolic syndrome

Experimental Physiology, EarlyView.
Abstract The antihypertensive mechanism of sodium–glucose cotransporter 2 (SGLT2) inhibitors has been traditionally attributed to osmotic diuresis. However, emerging evidence reveals multifaceted mechanisms beyond diuresis, including regulation of the renin–angiotensin–aldosterone system, sympathetic nervous system suppression, ion homeostasis ...
Chunxiang Xu, Xingyu Qiu, Nan Xu, Gensheng Zhang, Enyin Lai, Liang Zhao   +5 more
wiley   +1 more source

Cardiac remodelling in type 2 diabetes: Pathophysiological mechanisms and opportunities for multiscale computational modelling and simulation

The Journal of Physiology, EarlyView.
Abstract figure legend Overview of multiscale cardiac remodelling in type 2 diabetes and how to model and simulate these changes using a human‐based, multiscale computational framework. Cardiac remodelling in type 2 diabetes occurs at ionic channel, protein, cellular, tissue and whole‐organ level, affecting the electrophysiological function, mechanical
Ambre Bertrand, Jakub Tomek, Blanca Rodriguez   +2 more
wiley   +1 more source

Hepatic Glycogen Storage Diseases in Brazil: A Multicenter Study

American Journal of Medical Genetics Part A, Volume 200, Issue 7, Page 1591-1600, July 2026.
ABSTRACT To describe clinical and laboratory characteristics, emphasizing the evolution of patients with hepatic glycogen storage diseases (GSDs) followed in Brazilian reference centers. Multicenter, retrospective study involving 13 centers, using RedCap platform. 132 patients were included: 63 (47.8%) GSD type I (56 Ia, 7 Ib), 13 (9.8%) with type III (
Mariana Pena Costa, Alexandre Rodrigues Ferreira, Adriana Teixeira Rodrigues, Rodrigo Rezende Arantes, Thais Costa Nascentes Queiroz, Elisa de Carvalho, Gilda Porta, Irene Kazue Miura, Maria Tereza Galvão Guiotti, Rafaella Karen Sousa Monterlei, Adriana Maria Alves de Tommaso, Gabriel Hessel, Maria Ângela Bellomo‐Brandão, Roberta Vacari de Alcantara, Maria Julia Rodrigues Teixeira de Araujo, Daniela Góis Meneses, Regina Sawamura, Cibele Dantas Ferreira Marques, Lucas Rocha Alvarenga, Marise Helena Cardoso Tofoli, Ana Cristina Vieira de Melo, Jussara Melo de Cerqueira Maia, Leticia Helena Caldas Lopes, Eleonora Druve Tavares Fagundes   +23 more
wiley   +1 more source

Hyperglycemic Hyperosmolar Syndrome With Higher Brain Dysfunction in Which Arterial Spin Labeling Revealed Abnormal Cerebral Blood Flow: A Case Report

Clinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT Treatment for hyperglycemic hyperosmolar syndrome (HHS) was initiated for a transferred unconscious patient. Aphasia and agnosia remained even after metabolic improvement. Arterial spin labeling (ASL) indicated increased blood flow in the left temporal and parietal lobes.
Go Yoshimichi
wiley   +1 more source

Pharmacokinetic interactions between three SGLT2 inhibitors and telmisartan: A focus on empagliflozin, ertugliflozin, and henagliflozin. [PDF]

PLoS One
Zhou X, Deng Y, Guo C, Li Y, Fu Y, Wang Z, Dong Z.   +6 more
europepmc   +1 more source

The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 5, July 2026.
ABSTRACT Aims The use of pharmacotherapies with weight loss properties for the management of obesity and chronic disease are now routinely prescribed. We investigated the evidence from randomised‐controlled trials for the effects on lean body mass of glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) and sodium‐glucose co‐transporter‐2 inhibitors ...
Rishi Jobanputra, Jack A. Sargeant, Tatiana Plekhanova, Emily James, Abdullah Almaqhawi, David R. Webb, Melanie J. Davies, Thomas Yates   +7 more
wiley   +1 more source

Empagliflozin in HNF1A-MODY (MODY3): A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. [PDF]

Diabetes Care
Maagensen H, Høyerup SO, Jensen JS, Thuesen ACB, Forman JL, Thomsen HH, Vestergaard H, Knop FK, Hansen T, Hædersdal S, Støy J, Vilsbøll T.   +11 more
europepmc   +1 more source

Serum Advanced Glycation End Products as Drivers of Poor Tendon Outcomes in Diabetes? An Emerging Hypothesis and Narrative Review

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.
Tendon injuries in diabetes heal poorly, with unclear drivers of extracellular matrix disruption and altered mechanics. This narrative review synthesizes in vitro, animal, and human studies, highlighting serum advanced glycation end products as potential systemic contributors.
Eric J. Gutierrez, Lauren E. Mitevski, Jacob M. Haus, Chad C. Carroll   +3 more
wiley   +1 more source